Drug Discovery Alliance

Drug Discovery Alliance

Chiome Bioscience uses the ADLib® system to conduct joint antibody drug discovery and development with our alliance partners.

Partnering with pharmaceutical manufacturers inside and outside Japan, Chiome Bioscience uses the ADLib® system to generate high valued-added therapeutic antibodies.

Advantages for our Clients

  • Enabling the generation of antibodies to antigens that cannot be captured by conventional antibody generation technologies.
  • Enabling the generation of antibodies having different antigen recognition sites than those obtained by conventional techniques.
  • Enabling to provide candidate antibodies within about 10 days of obtaining the antigen.
  • All of Chiome Bioscience’s unique know-how, based on our extensive experience is put into antibody generation.

R&D Flow

Partnering with pharmaceutical manufacturers inside and outside Japan, Chiome Bioscience Inc. uses the ADLib® system to generate antibodies chiefly for the purpose of developing therapeutic drugs. Chiome Bioscience provides antibodies tailored to the needs of our partners through joint R&D with them and through contract research. Our partners then analyze the functions of the antibodies provided and study their potential to become drugs.